Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2020

View Archived Issues

iPSCs find best therapy for Best disease

Terns and Hansoh enter collaboration and license agreement for TRN-000632 in Greater China

Proof of concept seen with CAR T cells targeting chondroitin sulfate for treating bladder cancer

Bayer presents promising preclinical and phase I data for BAY-2433334

Novel mouse model of AAA with intraluminal thrombus

Kyorin Pharmaceutical discloses new 15-hydroxyprostaglandin dehydrogenase inhibitors

New MGAT2 inhibitors discovered at Shionogi

Incyte synthesizes new STING receptor agonists

Lilly discovers interleukin-17 receptor A antagonists

Genetic variant combination in MPIG6B and SH2B3 genes leads to myelofibrosis and thrombocytopenia

Astrogen identifies new serine derivatives

Screening in serum yields potential antibiotics against drug-resistant K. pneumoniae

Positive topline data presented from phase IIa ACTION study of DMX-200 in FSGS

Apogenix receives regulatory approval in Russia for phase II study of asunercept in COVID-19

Arrowhead initiates phase II study of AMG-890

First patient dosed in phase I/II study of RP-3500

Constant Therapeutics initiates phase II study of TXA-127 for COVID-19

Enterome begins clinical evaluation of cancer multipeptide therapeutic vaccine EO-2401

Phase I trial evaluates IBS therapy SMP-100 in healthy volunteers

INSPIRE trial of rigosertib reaches required survival events for data analysis

Noxopharm advances Veyonda for prostate cancer and COVID-19

ONC-392 moves into first-in-human study in advanced solid tumors and NSCLC

AL-001 normalizes progranulin levels in patients with GRN gene-mutation frontotemporal dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...